Skip to main content

About Us

A talent-driven, innovation-led biopharmaceutical company built on the research strength of Westlake University and Westlake Laboratory.

Bringing scientific innovation
to patients

Westlake Pharmaceuticals (Hangzhou) Co., Ltd. was founded in September 2020 and is headquartered in Hangzhou. Building on the research foundations of Westlake University and Westlake Laboratory, the company integrates cell biology, structural biology, medicinal chemistry and artificial intelligence to discover innovative drugs for major human diseases.

Our founding team is led by Dr. Hongtao Yu, a world-renowned cell biologist and Dean of the School of Life Sciences at Westlake University, together with Dr. Hu Qi and Dr. Jing Huang, Distinguished Research Fellows at the School of Life Sciences, Westlake University. Grounded in a deep understanding of the life sciences, the team builds an innovation and collaboration system dedicated to first-in-class drug discovery for major human diseases.

Founded in Hangzhou
2020
DEL compounds screened
49B+
First-in-class drug approved
1

Our values

A gloved hand pipetting into a flask of green solution in the laboratory
  1. Begin with the end in mindReach every patient

  2. Bold in innovationRigorous in evidence

  3. Open and inclusiveAcross disciplines

  4. Equal partnershipSeamless collaboration

Founding team

  1. Dr. Hongtao Yu

    Dr. Hongtao Yu

    Co-founder & Chairman

    Co-founded Westlake Pharmaceuticals in 2020 and serves as Chairman. He is an internationally renowned cell biologist and currently serves as Dean of the School of Life Sciences at Westlake University.

    Holds a bachelor’s degree in chemistry from Peking University and a Ph.D. from Harvard University, and carried out postdoctoral research at Harvard Medical School. He has served as assistant professor, associate professor and professor in the Department of Pharmacology at the University of Texas Southwestern Medical Center, and as the Serena S. Simmons Distinguished Chair, while also serving as an investigator of the Howard Hughes Medical Institute (HHMI).

    Elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2012, and elected to the board of the Society of Chinese Bioscientists in America in 2018.

  2. Dr. Hu Qi

    Dr. Hu Qi

    Co-founder & Director

    Co-founded Westlake Pharmaceuticals in 2020 and serves as a Director. He is a Distinguished Research Fellow at Westlake University.

    Holds a bachelor’s degree in pharmacy from Peking University, a master’s degree in medicinal chemistry and a Ph.D. in biology from Tsinghua University, and carried out postdoctoral research at the University of California, San Francisco, supported by a postdoctoral fellowship from the Damon Runyon Cancer Research Foundation.

  3. Dr. Jing Huang

    Dr. Jing Huang

    Co-founder & Director

    Co-founded Westlake Pharmaceuticals in 2020 and serves as a Director. He is a Distinguished Research Fellow at Westlake University and a leading figure in computer-aided drug design (CADD) and AI-aided drug design (AIDD) in China.

    Provides scientific advisory consulting to AI pharmaceutical companies such as XtalPi and DP Technology, as well as to leading internet companies including ByteDance, Baidu (BioMap) and Tencent, and collaborates with them on related research.

    Holds a bachelor’s degree and a master’s degree in physics from Tsinghua University and a Ph.D. in chemistry from the University of Basel, Switzerland, and carried out postdoctoral research at the University of Maryland School of Pharmacy and at the NIH/NHLBI.

Our history

2020 — 2026
  1. Sep 2020 · Founded in Yunqi Town, Hangzhou
    2020Sep

    Founded in Yunqi Town, Hangzhou

  2. Dec 2020 · Completed the angel financing round
    2020Dec

    Completed the angel financing round

  3. Sep 2022 · China’s NMPA cleared our first original drug, WPV01 (iscartrelvir), to enter clinical trials
    2022Sep

    China’s NMPA cleared our first original drug, WPV01 (iscartrelvir), to enter clinical trials

  4. Nov 2022 · Completed the Series A financing round
    2022Nov

    Completed the Series A financing round

  5. Oct 2023 · Completed the Phase 3 clinical trial of iscartrelvir
    2023Oct

    Completed the Phase 3 clinical trial of iscartrelvir

  6. Sep 2025 · Started IND-enabling studies for our first oncology candidate
    2025Sep

    Started IND-enabling studies for our first oncology candidate

  7. Jul 2026 · China’s NMPA granted conditional approval to Mprosevir® (iscartrelvir), our first original drug
    2026Jul

    China’s NMPA granted conditional approval to Mprosevir® (iscartrelvir), our first original drug

01 / 07

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Address
Building 3, 2/F, No. 1 Yumeng Road, Zhuantang Subdistrict, Xihu District, Hangzhou, Zhejiang

For partnership, recruitment or media enquiries, please write to us by email or call us directly.

Map showing the location of the Westlake Pharmaceuticals headquarters in Hangzhou
Map © Amap (审图号 GS(2018)1709号)Open in Amap ↗